[T]he UAE Ministry of Health recommend[s] that companies that produce products containing [finasteride] add [muscle weakness and stiffness] to the internal leaflet of their products.

Health Canada recently recommended adding a warning to products containing [finasteride]… While being administered the above-mentioned drug, patients may develop muscle weakness and stiffness, which in turn may cause pain to the patient, damage to muscle tissue and an increase in kinase enzymes. Accordingly, Health Canada and the UAE Ministry of Health recommend that companies that produce products containing [finasteride] add the above-mentioned warning to the internal leaflet of their products.

—Adding a warning to pharmaceutical preparations containing the medicinal substance finasteride: Administrative Circular No. (2009) of 2017